Podcasts about Takeda

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

On this week's episode, Chris Garabedian, Brian Skorney, and Sam Fazeli open with optimism about the biotech market, predicting an upcoming acceleration in IPO activity. In deals and financing news, the co-hosts discussed Summit Therapeutics' $500 million raise, with more than half coming from insiders, and continued momentum in M&A, including Alkermes' $2.1 billion acquisition of Avadel for its narcolepsy drug. The group also highlighted Takeda's $1.2 billion oncology deal with Innovent. European biotech funding showed positive signs, evidenced by Tubulis' $360 million Series C. Next, the co-hosts recapped ESMO, spotlighting Summit and Akeso's NSCLC data, Incyte's KRAS G12D inhibitor, and Arcus and AstraZeneca's TIGIT data. The episode concluded with additional data readouts, including mixed results from Alector and GSK's dementia drug, and Moderna's CMV mRNA vaccine results. *This episode aired on October 24, 2025.

Keizo Takemi, recent Japan Minister of Health, Labour and Welfare (September 2023-October 2024), shares his personal story that took him to Taiwan, CNN/Japan, the Diet, Harvard, back to the Diet, and recently into the cabinet of then Prime Minister Kishida. Along the way he became a leading force in charting Japan's approach to global health. As Minister he put a spotlight on the thousands of single, isolated elderly who die alone in Japan, unnoticed for days. Though expensive, wearable digital technologies can help connect the elderly better to community health services. Covid-19 exposed the lack of digitalized data and the need for a national mechanism to integrate patient and hospital data. That became a priority for him as Minister, as well as the creation of the Japan Institute of Health Security, a merger that promises far greater capabilities in preparing for and responding to dangerous outbreaks. By 2035, Japan will have 10 million citizens above 85 years of age. "Speedy aging" is raising demands for different care, at considerable expense. Achieving a stable number of skilled caregivers requires better wages and work conditions, and the entry of far more migrants into the workforce. Japan's biopharmaceutical industry requires a wholistic industrial policy. That sector is hollowing out, as Takeda and Astellas locate their operations in the United States.

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal changes and innovations shaping the industry landscape.Let's begin with a significant acquisition that is resonating across the sector. Alkermes has strategically acquired Avadel Pharmaceuticals for a noteworthy $2.1 billion. This acquisition is primarily aimed at Avadel's long-acting narcolepsy drug, Lumryz. This move not only acts as a growth catalyst for Alkermes but also strategically positions the company to potentially advance its own narcolepsy candidate, Alixorexton. This acquisition highlights a broader trend within the industry: a shift towards consolidation and specialization in niche therapeutic areas, reflecting the ongoing strategic maneuvering within the pharmaceutical sector to enhance therapeutic portfolios.In regulatory developments, there is an ongoing discussion around FDA cancer drug policies that's gaining attention. Eli Lilly's Oncology President has highlighted the need for clearer regulatory pathways. The debate revolves around whether to prioritize survival metrics without crossover incentives or encourage U.S. participation through crossover designs. This underscores a tension between maintaining regulatory rigor and offering flexibility in clinical trial design—a balance that impacts how quickly new oncology therapies can reach patients.Turning to international trade, there are significant movements as the Trump administration initiates a probe under Section 301 of the Trade Act of 1974. The aim is to assess if foreign nations are contributing their fair share to drug costs. Such an investigation could lead to tariffs, potentially altering global pharmaceutical trade dynamics and influencing international pricing strategies. Reports suggest that former President Donald Trump is exploring strategies to impose tariffs on U.S. trading partners not adequately compensating for pharmaceuticals, reflecting ongoing tensions regarding international drug pricing.Technology is revolutionizing life sciences commercialization strategies, with AI playing a pivotal role. Despite many organizations not being fully prepared for this digital shift, companies like Real Chemistry are pioneering AI applications to navigate regulatory complexities such as FDA marketing compliance. This digital transformation is set to redefine how pharmaceutical companies engage with patients and healthcare providers, enhancing efficiency and compliance.In legal news, Regeneron has settled a patent dispute with Celltrion over Eylea, allowing for the launch of a biosimilar by the end of 2026. This settlement is part of the growing biosimilars market, which offers cost-effective alternatives to high-priced biologics and enhances patient access to essential therapies.The industry's focus on oncology is further exemplified by Takeda's $1.2 billion upfront payment to Innovent Biologics for cancer assets. This deal includes substantial milestone payments, marking oncology as a key growth area post-Entyvio era and highlighting the high stakes associated with breakthrough cancer therapies. Continuing with significant industry maneuvers, Takeda Pharmaceuticals has announced a potential investment up to $11.4 billion to acquire three antibody-drug conjugates from Innovent Biologics. This deal includes an upfront payment of $1.2 billion and up to $10.2 billion in milestone payments—highlighting Takeda's commitment to expanding its oncology portfolio with innovative therapies that promise enhanced treatment outcomes for cancer patients.Ipsen's acquisition of ImCheck Therapeutics for $1.6 billion further emphasizes this focus on novel cancer treatments. The move includes ImCheck's mid-stage leukemia monoclonal antibody ICT01—an asset aimed at acute myeloid leukemia—indicating Ipsen's strategic push intSupport the show

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

On the Huh caught up with front man Josh Harrison backstage at the Waterfront after their soundcheck and ahead of a home town album launch show to celebrate the release of their new album In Venus train.Thematically In Venus Train channels mystical figures from folk-lore and biblical metaphors, writing songs about obsession, love and grieving a past life. The album is a musically rich, at times intricate and thoughtful, at others explosive and intense journey through the bands blend of melancholic, organic folk and sprawling, fuzzy alternative -rock. Drawing influence in equal measure from British Folk revivalists Fairport convention and alt-metal icons Tool, the album fuses melodic and emotional sensibility of folk with the noise and fuzzed guitar tones of grunge, ultimately making music that sounds something like if Nick drake joined Pile.Pop over to the website (www.onthehuh.org) it has lots of links to other bands stuff and venues as well as a link to an ever evolving Spotify playlist of Norwich bands material compiled by pod producer Reuben Andrews called La musique de Norwich.chin chin

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the rapidly evolving landscape of the pharmaceutical and biotech sectors, where regulatory updates, strategic mergers, and scientific breakthroughs are continually reshaping the industry.Starting with Novo Nordisk's recent challenges, their newly acquired manufacturing facility in Indiana has been flagged by the FDA with an "Official Action Indicated" designation. This classification, being the most severe level of inspection categorization, potentially signals delays in production and collaboration with partners like Regeneron and Scholar Rock. Such regulatory hurdles underscore the vital importance of compliance in ensuring smooth supply chains and market availability of therapeutics. It's a stark reminder of how critical regulatory oversight is in maintaining quality assurance within pharmaceutical manufacturing.Meanwhile, Johnson & Johnson is navigating its own regulatory landscape by engaging with the Trump administration on drug pricing reforms. These discussions highlight the broader industry's ongoing efforts to adapt to evolving regulatory frameworks and market dynamics. By spinning off its orthopedics unit, J&J aims to sharpen its focus and drive growth in more strategic areas, illustrating a trend towards specialization as companies strive to align with market demands.In mergers and acquisitions news, BioCryst Pharmaceuticals has completed a significant $700 million acquisition of Astria Therapeutics. This move positions BioCryst to compete directly with Takeda's hereditary angioedema therapy, Takhzyro. The acquisition emphasizes the competitive nature of specialty markets and highlights how targeted acquisitions can expand therapeutic pipelines.Halozyme Therapeutics is similarly active in pursuing mergers and acquisitions to enhance its drug delivery capabilities. Their recent acquisition of Elektrofi aligns with Halozyme's strategy to innovate in drug delivery technologies, which are increasingly recognized for their role in improving therapeutic efficacy and patient experience.Funding models are also evolving within the industry as alternative programs for specialty drugs gain attention for their potential cost-saving benefits for self-insured employers. However, these models raise ethical concerns due to potential financial risks shifting onto patients. This ongoing debate underscores the complexity of balancing cost management with patient access in healthcare.BioNTech's initiative to establish mRNA vaccine production facilities in Africa represents a significant step towards enhancing vaccine accessibility and equity on a global scale. Supported by European Union funding, this move underscores the importance of regional manufacturing hubs in facilitating rapid distribution of life-saving vaccines.Turning our focus to clinical advancements, Roche and Eli Lilly's collaboration has led to FDA approval of an Alzheimer's blood test for primary care use. This diagnostic tool could significantly enhance the adoption of Alzheimer's treatments like Biogen's Leqembi by streamlining diagnosis processes in primary care settings.Novo Nordisk's Indiana facility has again made headlines due to FDA scrutiny, potentially impacting partnerships with major players such as Regeneron. This situation highlights how stringent compliance requirements can influence strategic partnerships and operational timelines.On a promising note, Kailera Therapeutics has raised $600 million in funding to advance its obesity treatment program into Phase 3 trials. With Bain Capital leading this round, it reflects investor confidence in targeting metabolic disorders—a growing area of focus given their widespread health implications.Artificial intelligence continues to reshape drug discovery processes. Takeda Pharmaceuticals' $1 Support the show

Johnson & Johnson kicked off Q3 earnings season on Tuesday with the announcement that it is splitting its orthopedics and medtech operations and that it has yet to reach a drug pricing deal with the White House, though CEO Joaquin Duato did say those discussions are ongoing.  In advance of its Nov. 5 earnings call, Novo Nordisk, under the direction of new CEO Maziar Mike Doustdar, has been busy making moves, doubling down on MASH last week with its $5.2 billion buy of Akero. Then this week, Novo became the latest company to cut cell therapy, following Takeda's recent exit from the space. Meanwhile, as the government shutdown continues, so too does the chaos at the CDC, where more than 1,000 employees received termination notices last Friday—only for hundreds to be told never mind. At the FDA, however, there is some consistency despite the overhaul, with the agency on track for an average number of approvals this year. And a recent report on breakthrough designations shows that the regulatory award often leads to an FDA greenlight. On the legislative front, the BIOSECURE Act is back, as a slimmed down version passed the Senate last week as part of the defense spending bill. The latest version of BIOSECURE, which is meant to distance American biopharma from Chinese collaborators, doesn't name specific companies as previous iterations did and must still gain the Senate's support. 

Kooperation ist kein Schlagwort, sondern die Lebensader von Innovation. Gerade ineinem kleinen Markt wie Österreich entscheidet Zusammenarbeit darüber, ob eineIdee im Labor stecken bleibt oder den Sprung in die Welt schafft.In Folge 5 der Serie „From Science to Business“ zeigen Robert Schimpf, Co-Founder & Director des ­ InnCubator Innsbruck, und Manfred Rieger, Geschäftsführer und Standortleiter Forschung & Entwicklung bei Takeda Österreich, welche Mechanismen erfolgreiche Kooperationen ausmachen – von der ersten Geschäftsidee bis zum globalen Leuchtturmprojekt.

Ozlem Goker-Alpan, MD, Founder and President, Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) and Raphael Schiffmann, MD, of the Texas Christian University, discuss best practices to identify and treat neurologic problems associated with lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees. To complete the program and obtain credit, visit https://checkrare.com/learning/p-lysosomal-disorders-and-the-brain/ Support for this educational activity provided by Takeda and Ultragenyx.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the role of the neurologist in the team approach to careList best practices to assess neurologic and cognitive involvement  in persons with LDsCite best practices to assess developmental delay and regression in pediatric patients with suspected LDsDescribe the latest clinical research to improve central outcomes in persons with LDs and central nervous system involvementFacultyOzlem Goker-Alpan, MD, Founder and President, Lysosomal & Rare Disorders Research & Treatment Center (LDRTC), Fairfax, VA Raphael Schiffmann, MDTexas Christian University,Fort Worth, TXDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Ozlem Goker-Alpan MDDr. Goker-Alpan is on the Advisory Board/Consultant for Chiesi, Takeda, Sanofi, Prevail/Lilly, Sparks Therapeutics, Uniqure, Exegenesis, Astellas, Freeline, Team Sanfilippo. She receives grants/research support from Chiesi, Sanofi, Takeda, Prevail/Lilly, Spark Therapeutics, Amicus, Freeline, Sangamo, Cyclo, Odorsia, $DMT, Homology, Protaliz. She is on the speaker bureau for Sanofi, Takeda, Amicus, Chiesi.Raphael Schiffman, MDDr. Schiffmann is consultant for Amicus Therapeutics, Protalix Biotherapeutics, Chiesi Farmaceutici and 4D Molecular TherapeuticsMitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer. PhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesContinuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsCategory 2 CEUThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Genetic counselors should claim only the credit commensurate with the extent of their participation in the activity.CME InquiriesFor all CME policy-related inquiries, please contact us at mailto:ce@affinityced.comSend customer support requests to mailto:cds_support+ldrtc@affinityced.comCopyright© 2025. This CME-certified activity is held as copyrighted © by Lysosomal and Rare Disorders Research and Treatment Center (LDRTC) and AffinityCE. Through this notice, Lysosomal and Rare Disorders Research and Treatment Center (LDRTC) and AffinityCE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Zenas has made a $2 billion bet on autoimmune diseases with Chinese firm InnoCare, focusing on the development of orelabrutinib for multiple sclerosis. Former FDA director Peter Marks has joined Eli Lilly, marking the company's continued push in China. Sanofi's advancements in radiopharma, Boehringer Ingelheim's breakthrough in idiopathic pulmonary fibrosis, and Takeda's exit from cell therapy are also top stories. Cytiva filtration is highlighted as a solution for maintaining product integrity in biopharma.Biospace profiles the five most powerful women leading smaller biopharmaceutical companies, as the industry sees a shift with the departure of GSK CEO Emma Walmsley. A survey by CRB reveals that most life sciences companies are not planning new investments after tariffs, with big pharma taking the lead in manufacturing initiatives. Drug pricing criticism often overlooks the dynamic nature of drug pricing over time. Takeda's journey in building a cell therapy portfolio, only to ultimately walk away, is explored. Pfizer wins the bid for Metsera, Amgen offers Repatha at a discounted rate, and Roche acquires Akero for $3.5 billion. Biospace also honors 40 under 40 winners making an impact in the industry.Peter Marks, former director of the FDA's Center for Biologics Evaluation and Research, has taken on a new role as Senior Vice President for molecule discovery and the head of infectious diseases at Eli Lilly. Marks' controversial exit from the FDA led to his hiring by Lilly, following in the footsteps of another former FDA official, Rachael Anatol. Marks confirmed his new role to Stat News and began his first day at Lilly Research Laboratories on Monday.Support the show

The U.S. government is now in its second week of a shutdown—with the FDA having paused acceptance of all new drug applications for the duration. But it was business as usual at the CDC, which adopted the recent recommendations of its newly revamped advisory committee on chickenpox and COVID-19 vaccines. And another senior leader, National Institute of Allergy and Infectious Diseases Director Jeanne Marrazzo, was fired last week, after filing a whistleblower report.  Across the country, cell and gene therapy leaders arrived in Phoenix for the annual Meeting on the Mesa, as the space remains in a state of flux—with regulatory and M&A momentum being stalled by commercial and market challenges. Takeda, for one, is looking to offload its cell therapy platform after years of hefty investment.  President Donald Trump's long-awaited tariffs did not hit on Oct. 1 as promised. But in the face of the looming levies, Pfizer signed a drug pricing deal with the White House that provides a three-year exemption. Amgen appears to be climbing onboard as well, announcing that its lipid-lowering drug Repatha will be available at a steep discount. These moves are all well and good for Big Pharma players, but a recent report from CRB reveals most smaller biopharma companies are not planning any investments to offset tariffs.  In our weekly weight loss segment, Skye Bioscience's cannabinoid receptor 1-targeting candidate nimacimab failed to outpace placebo in reducing body weight but elicited “intriguing synergy” in combination with Novo Nordisk's Wegovy, according to William Blair analysts. And regulatory documents shed further light on Pfizer's $4.9 billion takeover of Metsera, in which the New York pharma beat out two higher bidders for the promising obesity startup.  Finally, make sure to check out The 5 Most Powerful Women in Biopharma and BioSpace's inaugural 40 Under 40, highlighting 40 young leaders who have made an impact on the biopharma industry.  

Finanzierung ist bei forschungsintensiven Spin-offs kein Sprint, sondern ein Marathon. Lange Entwicklungszyklen, hohe Kosten und komplexe Eigentümerstrukturen stellen Gründer:innen und Investor:innen gleichermaßen vor Herausforderungen.In Kapitel 4 unserer Serie „From Science to Business“ diskutieren:Doris Agneter (Geschäftsführerin, tecnet equity),Lukas Rippitsch (Portfolio Support Lead, Noctua Science Ventures) undThomas Meneder (Geschäftsführer, OÖ HightechFonds),Die Runde zeigt, welche Rahmenbedingungen Österreich braucht, um forschungsintensive Spin-offs langfristig erfolgreich zu machen."From Science to Business“ setzen wir gemeinsam mit unseren Partnern AplusB (Academia plus Business), Austria Wirtschaftsservice (aws), MedLifeLab Innovation Hub (Medizinische Universität Innsbruck), Noctua Science Ventures, JKU – LIT Open Innovation Center (Johannes Kepler Universität Linz), OÖ HightechFonds, Spin-off Austria, Takeda, tecnet equity, The Spinoff Factory (Technische Universität Wien), Universität Innsbruck und WU (Wirtschaftsuniversität Wien) um.

 The Transformative Power of "Thank You"The story of Wahei Takeda (Japan's Warren Buffett) and the desperate jobseeker reveals a profound truth: Gratitude isn't just a feeling—it's a financial and spiritual force.How "Thank You" Rewires Your Brain (and Bank Account)    The 1-Yen Miracle        The jobless man was told: "Say ‘thank you' 3,300 times a day for a month, and I'll pay you 100,000 yen."        At first, it seemed absurd. But within weeks, his mindset shifted:            He noticed hidden opportunities in rejections.            He appreciated his family despite their struggles.            He radiated positivity, transforming his job interviews.        Result: He returned not just richer, but unstoppable.    The Science of Gratitude        Studies show gratitude boosts serotonin (the "happiness chemical") and reduces cortisol (the stress hormone).        People who practice gratitude earn 7% more on average—not from luck, but because they attract opportunities .    My Near-Death Testimony        After a paralyzing accident, doctors said I'd never walk again.        Instead of despair, I repeated: "Thank you, God, for my life."        Eight hours later, I stood up and left the hospital.        My vision was blurry, my body traumatized—but gratitude rewired my recovery.The "Thank You" ChallengeWant to test this power? For the next 30 days:    Say "thank you" 100+ times daily (to cashiers, strangers, even frustrations).    Journal 3 gratitudes every night (e.g., "Thank you for the bus arriving on time").    Silently thank God (or the universe) during hardships (e.g., "Thank you for this lesson").Watch what happens:    Opportunities find you.    People help you unexpectedly.    Your mind spots solutions, not problems.Why Billionaires Like Takeda Teach ThisWarren Buffett, Oprah, and Tony Robbins all credit gratitude as their "secret weapon."    Buffett starts his day listing things he's grateful for.    Oprah kept a gratitude journal for decades.    Takeda knew: Money flows to those who appreciate life first.Final ThoughtThe man in Takeda's story didn't get rich from the 100,000 yen. He got rich because gratitude made him magnetic.Your turn. Start today. One "thank you" at a time.Question: What's the one thing you'll thank God/universe for today? (Reply, then act on it.)

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Former NIAID director Jeanne Marrazzo was fired after filing a whistleblower report, alleging retaliation. The FDA's new cell and gene therapy guidances have been well-received for streamlining therapies. In other news, CMS has finalized stronger protections for orphan drugs, and Amgen's Repatha has shown positive results in preventing heart disease. Lotte Biologics is highlighted as a multinational CDMO partner, and layoffs at CSL Vifor and Takeda are noted. Trump has delayed pharma tariffs, Pfizer's drug pricing deal with Trump raises questions, and GSK CEO Emma Walmsley's departure is discussed. Thank you for listening to the latest updates in the Pharma and Biotech industry. Stay tuned for more essential news in our next episode.Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. President Trump has once again delayed the imposition of 100% tariffs on pharmaceuticals, with preparations now set to begin on October 1. Halozyme's acquisition of Elektrofi for $900 million has brought two major pharmaceutical partners together, while Takeda is exiting the cell therapy sector and laying off 137 employees. Roche's $3.5 billion takeover of 89bio was driven by the success of Akero's drug, with regulatory documents shedding light on how 89bio's board pushed for the deal. Lotte Biologics is making waves as a multinational CDMO partner with a focus on quality and patient promise. In other news, GSK has announced layoffs, Pfizer has struck a drug pricing deal with Trump, and big pharma companies are exploring M&A funding opportunities. Stay tuned for more updates in the biopharma industry.Support the show

Österreichische Universitäten und Unternehmen arbeiten an Therapien, die Patient:innen real helfen – doch wie kommen Forschungsergebnisse in die Anwendung? Wie läuft die Entwicklung eines Arzneimittels wirklich ab, welche Hürden gibt es bei IP, Finanzierung und Regulierung – und worauf kommt es in Kooperationen zwischen Uni und Industrie an? Darum geht es in der dritten Folge von „From Science to Business“.Am Round-Table diskutieren:Christine Bandtlow – Vizerektorin für Forschung & Internationales, Medizinische Universität InnsbruckManfred Rieger – Standortleiter und Geschäftsführer des Forschungs- und Entwicklungsbereiches von Takeda in ÖsterreichIm Gespräch wird klar: Der Transferpfad in Life Sciences ist lang und komplex – erfolgreich wird er durch klare IP-Regeln, belastbare Finanzierungsmodelle, regulatorische Sicherheit und Kooperationen auf Augenhöhe."From Science to Business" setzen wir gemeinsam mit unseren Partnern AplusB (Academia plus Business), Austria Wirtschaftsservice (aws), MedLifeLab Innovation Hub (Medizinische Universität Innsbruck), Noctua Science Ventures, JKU - LIT Open Innovation Center (Johannes Kepler Universität Linz), OÖ HightechFonds, Spin-off Austria, Takeda, tecnet equity, The Spinoff Factory (Technische Universität Wien), Universität Innsbruck und WU (Wirtschaftsuniversität Wien) um.

In this special sponsored episode from Takeda, Angelina Collins, a Nurse Practitioner at a large tertiary inflammatory bowel disease (IBD) center in California, shares insights from her nearly two-decade journey in IBD care. She explores the challenges of diagnosing Crohn's disease and ulcerative colitis, from varied symptom presentation to limitations in early recognition. Emphasizing the potential consequences of delayed diagnosis—including disease progression and increased risk of complications—Angelina advocates for early identification of red flags and a multidisciplinary team approach to treatment and care. She highlights the critical role of advanced practice providers and the importance of expanding IBD knowledge across health care teams. Listeners will come away with insights on how to recognize red flags, apply best practices for timely referrals, and leverage collaborative care models in IBD management. READ THE ARTICLE → https://kevinmd.com/takeda Are you a health care clinician looking to increase your IBD knowledge? Visit IBDIQ.com, part of The IBD Project, to continue to evolve your IBD knowledge for yourself and your patients. Developed by Takeda in collaboration with IBD specialists and created for health care providers, IBDIQ is an on-demand educational platform, available at no cost, that offers timely, relevant information tailored to today's IBD care landscape: https://www.ibdiq.com/ Please note, no continuing medical education credits are offered through IBDIQ. VISIT SPONSOR → https://www.ibdiq.com/ SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

« Ce n'est pas parce qu'on ne sait pas exactement comment on va y arriver qu'on ne doit pas essayer. L'essentiel, c'est d'oser faire le premier pas. »Dans ce nouvel épisode de Pharma minds, j'ai le plaisir de recevoir Nienke Feenstra, Présidente de Takeda France. Nienke a un profil hors-norme, façonné par l'intuition, l'audace, une curiosité insatiable, et une vision profondément humaine du leadership.Dans ce laboratoire multicentenaire, elle impulse une dynamique de transformation aussi radicale que lucide.On parle transformation, IA, santé, inclusion, mais surtout de ce que signifie diriger dans un monde en rupture, avec tout ce que cela implique de lucidité, d'humanité, et de courage.Au programme :◾️ Le concept de "strategic selfishness" : une approche puissante◾️ Comment l'IA redéfinit les compétences : on parle de ce que l'humain doit continuer à cultiver dans un environnement où l'IA va tout bousculer, y compris les métiers les plus experts.◾️ Un leadership inclusif, même face à des opinions clivantes : elle partage des exemples concrets vécus en Pologne, où l'écoute, même inconfortable, devient une responsabilité managériale.◾️ Construire un objectif commun dans l'incertitude : chez Takeda, on ne parle pas de plan à 5 ans, mais d'un moonshot collectif et inspirant.◾️ Créer de la valeur au-delà du médicament : elle détaille la création d'un département pionnier en France, qui regroupe toutes les fonctions autour du patient pour co-créer avec l'écosystème des solutions durables.◾️ Préparer la pharma de demain : entre hôpitaux digitaux, prévention ultra personnalisée, et hybridation technologique, elle trace les lignes d'un futur où le patient aura plus de pouvoir.Bonne écoute !Merci à notre partenaire Takeda d'avoir rendu cet épisode possible, et de nous donner l'élan pour explorer de nouvelles perspectives en santé. Comme toujours, l'équipe Pharma Minds garde la main sur la ligne éditoriale et le choix des invités.__Pour retrouver Nienke Feenstra : LinkedIn : https://www.linkedin.com/in/nienkefeenstra2/?originalSubdomain=frTakeda France : https://share.google/587y8rLFkLAEqnryp__Ressources citées :

Whats up everyone my apologies for not posting a lot. A baby is a lot of work, and I can't mix when the creative juices are flowing aaaaannnnnnd I have to mix a a lower volume. So I have another shorty for you about 30min. So I hope you enjoy I will post as soon as I can.  1) Butterfly Effect (Paul T & Edward Oberon Remix)- Filthy Philip, PhoebeTrain & Paul T & Edward Oberon  2) Sapt Dub - Flaco & Jamal 3) For You - Kathryn Brenna & DLR  4) Penny Up - Script  5) Warrior - Bungle  6) Conditioned Reaction - Business as Usual  7) Raise Your Hands - Break & Solah  8) Hear That - KNOWMANS & Chorux 9) Keep It Moving - Kathryn Brenna, Minor Forms & Kublai 10) Point of No Return - Leks & Takeda  11) Books - The Sauce & Logan 12) Take Control - Business as Usual & Aria 13) Zeroday - Dub Head  14) Midnight Rider - Business as Usual  15) Move Kinda Different - Zero T & Fox  16) Represent - DKN  17) Everything is Rhythm - DKN 18) E92 - T>I  19) It's the Feel - Bladerunner  20) Inside - Bou & Simula  21) Try Again - Bou & Jack Banner  22) Raww - Dj Direkt  23) Work it - Gui  24) Turn up - Gui  

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview three high school students who made less invasive EoE diagnostics the focus of a science fair project. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship that exists between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:51] Co-host Ryan Piansky introduces the episode, brought to you thanks to the support of Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:08] Holly introduces today's guests, three high school students from Texas who made EoE diagnostics the focus of a science fair project: Leyna, Nhu, and Jaden.   [1:47] Leyna, Nhu, and Jaden are best friends. Nhu was diagnosed with EoE last summer. Leyna said Nhu told them it took a long time for the doctors to diagnose her because they thought it could be different conditions.   [2:07] Nhu told them about her appointments and her endoscopy procedures. She had to miss school sometimes. Leyna and Jaden were concerned for her.   [2:22] Leyna took AP Bio. Her teacher was a sponsor for the science fair. Leyna thought this would be a meaningful project for the three friends to learn more about Nhu's condition.    [2:45] Holly shares that she wasn't diagnosed until her 20s, but she was sick for much of her childhood.   [3:13] Ryan shares that he was diagnosed when he was two, after two years of his parents taking him to different doctors and undergoing different tests.   [3:31] Nhu says it was hard to find a specialist. They found one and had to wait six months for an appointment. It was a long time, suffering from the effects of EoE with constant symptoms, a lot of heartburn, and painful vomiting.   [4:00] Nhu was diagnosed with EoE in her sophomore year of high school. Her friends have seen her endure a lot, but she's strong. Nhu had to miss an orchestra concert where she had a big solo, because of her EoE.   [4:32] Doctors thought Nhu could have something different, like H. Pylori or cyclic vomiting syndrome. They didn't have clear answers, which was confusing and frustrating for her family.   [4:50] Holly talks about how difficult it was for her to get a diagnosis, and how she was told she was vomiting to get attention. She shared her reaction when diagnosed. She would like someone to do a research study about the pain tolerance of people with EoE.   [5:41] Leyna says junior year is the hardest year of high school. She doesn't know how Nhu survived physics and AP classes with EoE on top of it, and making up late work.   [6:14] Nhu takes a weekly injection. Her symptoms happen almost monthly. Sometimes she misses school for two weeks and has to catch up on work. Leyna and Jaden help her with her schoolwork.   [6:47] Ryan shared how he missed a third of his senior year in high school. He's now on an injectable biologic that has helped him a lot. That treatment option wasn't available when he was in high school. Having supportive friends to send him his schoolwork and keep him up-to-date was very helpful.   [7:11] Ryan explains the esophageal string test (EST). This is a tool that was developed to help monitor eosinophilic esophagitis (EoE). The test works by having the patient swallow a capsule about the size of a Tic Tac that has a string attached.   [7:25] The capsule dissolves in the stomach while the string stays in place in the esophagus. After about an hour, it's gently removed. Along the way, the string collects samples from the lining of the esophagus, which are reviewed, similarly to a biopsy.   [7:37] Holly adds that what makes the string test unique is that it doesn't require an endoscope, anesthesia, or recovery time, things that usually come with a traditional endoscopy and biopsy.   [7:46] It's now being used with patients as young as four years old. While some people might feel some minor discomfort, it's generally much easier for regular monitoring than an endoscopy.   [7:57] Holly explains that she was involved in testing the device and developing a swallowing protocol for it at Children's Hospital of Colorado. We will talk more about this later in the episode.   [8:06] Ryan adds, to learn more about the development of the string test, listen to episode 26 of this podcast.   [8:10] The string test is one of multiple, less-invasive monitoring tools for eosinophilic esophagitis. Others include the sponge test and unsedated trans-nasal endoscopy.   [8:19] To learn more about unsedated transnasal endoscopy, listen to episodes 19 and 20, where we talk to clinicians and patients about this method.   [8:27] During that episode, we talked to the developers of the EST.   [8:38] Jaden tells how he, Leyna, and Nhu brainstormed ideas and decided to base their project specifically on how to diagnose EoE in a less invasive way than endoscopies.   [9:12] Before this project, they were not familiar with the EST. Nhu says her only option for diagnosis was an endoscopy.   [9:21] Holly says it's still like that in Maine. She came from an area of the country where the EST was researched, and it's interesting to her that she doesn't have access to it now.   [9:37] What appealed to the group about the EST as an alternative to endoscopies is that it was so different. There are so many advanced technologies, and the EST is just a capsule taped to a string. It is simple but innovative.   [10:13] Real Talk: Eosinophilic Diseases had Drs. Robin Shandas and Steven Ackerman, who were instrumental in the development of the esophageal string test, as guests on episode 26 of this podcast. Ryan encourages listeners to check out that episode at apfed.org/podcasts.   [10:42] They searched for keywords and analyzed a variety of scholarly literature. They collected a lot of data from Dr. Ackerman's papers.   [11:10] They also reached out to gastroenterologists on social media. A hard thing about science fair projects is coming up with an experiment. They didn't know what they could do just with compiled research, but they had a great sponsor who helped along the way.   [11:56] Leyna says they trusted that the doctors they reached out to on social media were competent in their understanding of different diagnostic methods. She notes that different locations may have different resources and different biases.   [12:14] Leyna says they talked to doctors in the U.S. and from different countries, including India and Mexico. She commented that communities in Mexico might not have the same resources as communities in the U.S. or India. That might change their understanding of the EST.   [12:33] We might have different biases because we don't have the same technology to research and find the same things about the EST.   [13:12] Leyna says they reached out to doctors on social media, but didn't get responses from that many doctors. Reaching out to patients would be a good thing if they want to continue the project.   [14:00] Jaden says most of the data they found was from Dr. Ackerman, including a survey he did comparing the data of the EST and the biopsies.   [14:10] They found that the EST and the biopsies were relatively similar in terms of discovering the eosinophilic count and determining whether the EoE is active or inactive.   [15:30] They found differences between ESTs and biopsies in finding how much of a certain chemical is in the patient's cells.   [14:43] Leyna comments that one of the doctors they reached out to told them about the sponge test, another less invasive method. They didn't research the sponge test, but it sounded interesting.   [15:00] Ryan says there are a lot of cool new techniques that are being researched, like the transnasal endoscopy that goes in through the nose, the string test, and the sponge test.   [15:13] Leyna says the cool thing was hearing about all these methods. They had hypothesized that there are less invasive methods that may be better than endoscopies.   [15:27] They were not able to prove their hypothesis yet. They learned a lot of different things that could be beneficial.   [15:42] Holly points out that the transnasal endoscopy is not scary. It's also known as the unsedated endoscopy. Holly has done both the EST and the unsedated endoscopy,  and they each have pluses and minuses.   [16:15] Nhu explains how the team would meet at one of their houses, usually Leyna's house. One day, they watched Interstellar together, and the “Eureka moment” scene motivated them.   [16:41] They helped each other whenever necessary. When the project board was due, they all went to Leyna's house to work on the project board. They worked together as a team.   [16:51] Jaden analyzed a lot of the data. Leyna reached out to professors. Nhu helped Jaden understand some terms. On the day they presented the project, Nhu was sick in the hospital, which made them sad. They included a photo of her on the project board.   [17:28] Holly says that although Nhu wasn't there, it may have helped people know how sick EoE can make you feel.   [18:28] Leyna says one of the doctors they reached through social media told them that endoscopies have lots of benefits. The biopsy samples give healthcare professionals a clear idea of how many eosinophils per high-powered field, a key indicator in diagnosing EoE.   [18:57] The diagnosis gives a baseline for starting treatment for the patient, monitoring how effective the treatment is. You can't count the number of eosinophils per high-powered field using the string test.   [19:11] The EST is a gelatin capsule attached to a long string that you swallow. It dissolves in the stomach. It's less expensive than an endoscopy.   [19:33] Holly says one of the big differences is that you can't diagnose EoE on a string test. It has to be diagnosed with an endoscopy.   [19:40] Leyna says they learned that from the doctors and medical students who reviewed their project board. You can't diagnose EoE with the EST, but you can monitor it.   [19:52] The string test doesn't provide a direct eosinophil count, but it reflects the level of inflammation in your esophagus, and it can measure the protein biomarkers. That correlates with the eosinophil count from a biopsy. It is good for monitoring EoE.   [20:12] Ryan says that's a great idea. In the show notes, there is a link to the diagnostic consensus guidelines. They specify that you need an endoscopy and 15 eosinophils per high-powered field to be diagnosed with EoE.   [20:28] The EST can monitor the progression of the disorder as you're trying new medicines or an elimination diet. If you need an endoscopy every three to six months, it can be taxing.    [20:49] Ryan comments on the cost. Going through anesthesia for an endoscopy is very expensive, and not everyone has the insurance to cover these diagnostic procedures. The EST is an option you can do in a doctor's office in just over an hour.   [21:16] Holly asks if Nhu has participated in a string test. Nhu has not, but she would love to do a string test if she had the chance. Whenever she sees her doctor, she brings up her condition, and what could be better for her, such as the string test.   [22:06] The science fair is a huge regional fair in Houston, called the Science and Engineering Fair of Houston (SEFH). This was their first year participating. They were regional qualifiers from their district. When they got there, everyone else had six-foot-tall printed boards. It was a shock to them.   [22:56] They hope to level up their board for next year's fair. It was cool and eye-opening to see all these student researchers and get feedback from the people who walked by their booth. They heard some interesting things to use in their next project.   [23:15] One medical student in attendance came by their project board and suggested that while the EST may not diagnose EoE, maybe it could be used as a screening tool [to help identify people who should follow up with a gastroenterologist for a diagnostic work-up]. Interestingly, this was a medical student, and she had recently scheduled an appointment with a gastroenterologist for an endoscopy to see if she has EoE.   [24:04] This student didn't seem to know much about EoE, but felt she was experiencing symptoms that might indicate EoE. She told them she had learned so much from their board. Ryan says it's great that the project was able to help this person.   [24:44] Jaden says that the students at their school didn't know much about EoE, but when they looked at the project board, they were shocked by how incredibly difficult it is to diagnose EoE and how the EST could change a lot of things as a screening method.   [25:11] Jaden says their science teacher came by to see their board and how they were doing. He liked how they included not only the research information but also the stories of why they chose their project and why they were passionate about it.   [25:34] The day of the project, Leyna and Jaden were sad that Nhu couldn't be there with them. Their sponsor, Leyna's biology teacher, was sick, but showed up at the fair to view their presentation. They raised awareness about EoE. People learned about it.   [25:54] When Nhu told Leyna about her EoE, Leyna had no idea what it was. She's glad their project brought the issue to the table. They emphasized that more research needs to be done. There is much we don't know about less invasive methods.   [26:23] Nhu has considered a career in medicine since she has been in many hospitals and talked to a lot of doctors. Jaden sees himself in the engineering field, but he enjoys researching like this and seeing things through a different perspective.   [27:05] Nhu learned a lot about herself with EoE. Leyna loves how much they learned from this project. She is interested in pursuing scientific research. She thinks it's cool that Ryan is a graduate student.   [27:24] Leyna just got back from a five-week summer research program. It was insightful. She doesn't see herself becoming a doctor, but possibly doing research and advocating for different conditions.   [27:43] When Ryan was in high school, with all his hospital time, he had an interest in medicine, then he took a turn into engineering. He enjoys research. He's passionate about engaging in patient advocacy work through APFED.   [28:10] Ryan is glad for Leyna, Nhu, and Jaden that they were able to engage with this research and do it as a group and as friends. He says it's fantastic to hear from the group about the whole process they went through.   [28:23] Holly asks, looking back on everything you guys learned and experienced in this project, what's one question or idea you would still like to explore if you had more time and resources?   [28:38] Nhu wants to research finding more ways to diagnose EoE. Testing for EoE and finding EoE are very interesting for her.   [28:53] Jaden thinks that if they had more time, they would try to create a model of the EST to show how it works. He would possibly try to improve upon the model or develop something new. Instead of just relying on the data we have, he would try to collect data.   [29:26] Leyna agrees. She would like to build a prototype, understand how the capsule works, and find out whether the string down the esophagus is uncomfortable.   [33:41] Ryan suggests there is a doctor who would let them try the string test so they could see how it feels. Holly tried the string test at a major children's hospital while it was being researched. She doesn't want to ask her patients to do something she hasn't done, since she has the diagnosis too.   [30:37] Ryan comments that he enjoyed hearing about the process of the project.   [30:51] Ryan gives a quick recap: The esophageal string test is a tool to help monitor EoE. It is not a tool to diagnose EoE. If you or a loved one has EoE or suspect that you might, ask your clinician about the string test to see if it's an option for you.   [31:03] Holly adds: School science fairs are one way to bring education about eosinophilic disorders to schools. We love hearing about community science fairs and school projects that teach others about these conditions.   [31:13] For those of you looking to learn more about eosinophilic esophagitis, we encourage you to visit apfed.org/EoE.   [31:23] For those looking to find specialists who treat EoE, we encourage you to use APFED's Specialist Finder at apfed.org/specialist.   [31:30] Ryan thanks Leyna, Nhu, and Jaden for joining us today. Holly also thanks APFED's Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode: Dr. Robin Shandas Dr. Steven Ackerman “Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference”   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   “Nhu and Jaden are my best friends. Recently, Nhu was diagnosed with EoE. I remember her telling us about the long diagnosis process. It took the doctors quite a long time to diagnose her because they thought it could be different conditions.” — Leyna   “I thought that this would be a meaningful project for us to learn more about Nhu's condition [of EoE].” — Leyna   “The students at our school didn't know much about EoE, but when they looked at the project board, they were shocked by how incredibly difficult it is to diagnose EoE.” — Jaden   “One of the main benefits of the string test is that endoscopies can be quite expensive, especially the anesthesia. It could be beneficial for people who don't have the money for an endoscopy.” — Nhu

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

What if process intensification could transform your bioprocessing economics without the complexity most engineers fear? Getting 3x productivity gains and 30-150% titer increases once seemed reserved for Big Pharma's endless R&D budgets, but a strategic approach to technology selection is making these results achievable for companies of any size.In this episode, David Brühlmann speaks with Andreas Castan, a bioprocess veteran with over 25 years of industry experience who provides leadership and support to Cytiva's bioprocess business. Andreas brings deep expertise from directing upstream development at Swedish Orphan Biovitrum and extensive work in expression systems, process development, scale-up, and cGMP manufacturing across multiple therapeutic modalities.Why tune in? Here's your process engineer's roadmap:Process Intensification Economics Decoded: Andreas reveals the cost-benefit reality behind continuous vs fed-batch manufacturing, including real process economic modeling data showing why the differences aren't as dramatic as you'd expect and what factors actually drive your business case.Low-Hanging Fruit That Delivers: Skip the overhyped AI solutions. Andreas shares the strategic fundamentals that work: high-producing cell line development, N-1 perfusion for rapid productivity gains, and smart bioreactor turndown strategies that eliminate process steps without adding complexity.Decision Framework for Technology Selection: Learn when continuous processing makes economic sense (and when it doesn't), how media costs impact your COGS analysis, and why understanding your bottlenecks, not following industry trends, should drive your intensification strategy.Industry Insider Strategies: Get the inside track on what AstraZeneca, Sanofi, Merck, Lonza, and Takeda are actually implementing, plus Andreas's perspective on why human expertise and mechanistic insights still outweigh AI in real-world process decisions.Ready to make smarter technology investments and achieve measurable productivity gains? This isn't theory. It's a practical guide to process intensification economics that you can apply whether you're preparing for Phase I or scaling for commercial manufacturing.Connect with Andreas Castan:LinkedIn: www.linkedin.com/in/andreas-castan-91570b1Cytiva landing page: Process intensificationOnline tool: Process intensifierNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

The accredited CME program highlights the latest clinical research about hemophilia, a rare, genetic bleeding disorder. Led by Dr. Steven Pipe, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with hemophilia. This program is supported by an educational grant from Sanofi.To receive CME credit, visit https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hemophilia. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with hemophilia and its clinical relevance.Steven Pipe, MDProfessor of Medicine,University of Michigan Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Pipe discloses the following relevant financial relationships with ineligible companies:Consultant: Bayer, BioMarin, CSL Behring, Hema Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Poseida Therapeutics, Roche/Genentech, Sanofi, Takeda, Spark TherapeuticsScientific Advisory Committee: GeneVentiv, Equilibra BioscienceGrant/Research Support: Siemens, YewSaving Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

The accredited CME program highlights the latest clinical research about iTTP, a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in iTTP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with iTTP and its clinical relevance. Shruti Chaturvedi, MDAssistant Professor of MedicineJohns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This accredited CME program highlights the latest clinical research about immune thrombocytopenia (ITP), a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this program provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in ITP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with ITP and its clinical relevance.FacultyShruti Chaturvedi, MDAssistant Professor of Medicine,Johns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

On this week's episode, Chris Garabedian, Tess Cameron, EricSchmidt, Sam Fazeli, and Brad Loncar open with a look at the market environment as biotech sees its first IPO since February -- LB Pharma -- and financings, including Maze's $150M PIPE and Rapport's $250M follow-on. The co-hosts discuss improving sentiment around rates, the $XBI, and insights from conversations at the HC Wainwright conference. Novartis' $1.4B acquisition of Tourmaline Bio and broader deal-making dynamics are also highlighted. On thepolicy front, the group examines the latest China biotech news, including a draft executive order from the Trump Administration. The co-hosts debate access, geopolitical concerns, and the FDA's slower trial-startup process. Indata news, the co-hosts examine Revolution Medicines' pancreatic cancer therapy, emerging small-cell lung cancer data from the World Conference on Lung Cancer, Summit's mixed readout and market reaction, and promising newnarcolepsy data from Takeda and Alkermes. Dianthus' positive generalized myasthenia gravis results are also highlighted. Regulatory and safety updates cover the FDA's withdrawal of Intercept's liver drug, a patient death in Capsida's gene therapy trial, Soleno's FAERS-related stock drop, SEC action on Fibrogen data manipulation, and cancellations of several FDA ad comms raising transparency questions. The episode concludes with a discussion on BridgeBio accusing Alnylam and Pfizer of aggressive tactics in the ATTR-CM market, Arena Bioworks appointing veteran Harvey Berger as CEO, and Novo Nordisk's 11% workforce reduction. *This episode aired on September 12, 2025.

Changes are on the way for community health workers in Arkansas. Earlier this year, the Arkansas General Assembly approved the Community Health Worker Act, which will establish standardized training and a statewide certification process for community health workers and will allow those certified to receive compensation for their services from Arkansas Medicaid and private insurers. Unlike healthcare workers who operate in a clinical setting, though, community health workers may not have the infrastructure in place to make this transition seamlessly. To learn how other states have navigated similar transitions, we're joined by Colby Takeda, co-founder of Pear Suite, a hub for thousands of community health workers across the country.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview  Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.

温かさと厳しさを併せ持つ武田鉄矢が毎週テーマに添ってさまざまな語りを展開。どんな話題でも美味しくさばいて見せマス！さらに、Podcastでは配信されていない2006年以降の音源をお楽しみいただけるサービスが「QloveR」にて展開中！毎週月曜日に1週間分ずつアーカイブ音源が更新され、掲載されている音源は何度でも聴き放題です！ぜひご登録の上お楽しみください。登録はこちら→https://qlover.jp/takeda [毎週月曜更新]See omnystudio.com/listener for privacy information.